Functional and structural pathologies in skeletal muscle of a rat model of Duchenne muscular dystrophy

Young Il Lee1,2, Cora C Hart1,2, C Spencer Henley-Beasley2,3

  • 1Department of Pharmacology & Therapeutics, University of Florida, Gainesville, FL 32610.

Abstract

Insights

A new muscular dystrophy rat model (MDR) shows progressive muscle weakness and damage, mirroring Duchenne muscular dystrophy (DMD) in humans. This model is valuable for testing new DMD therapies.

Area of Science:

  • Biomedical Science
  • Genetics
  • Animal Models

Background:

  • Duchenne muscular dystrophy (DMD) is a fatal pediatric disease with no cure.
  • Effective preclinical models are crucial for developing DMD therapeutics.
  • Rat models offer a promising small animal platform for DMD research.

Purpose of the Study:

  • To develop and characterize a novel CRISPR/Cas9-generated dystrophin-deficient rat model for Duchenne muscular dystrophy.
  • To comprehensively assess skeletal muscle functional decrements in this new rat model.

Main Methods:

  • Generated a dystrophin-deficient Sprague-Dawley muscular dystrophy rat (MDR) using CRISPR/Cas9 gene editing.
  • Confirmed dystrophin loss via biochemical and immunofluorescent analyses.
  • Assessed in situ and ex vivo muscle function and performed histopathology at 3, 6, and 12 months.

Main Results:

  • MDR muscles showed complete loss of dystrophin and reduced dystrophin-glycoprotein complex members.
  • MDR rats exhibited progressive muscle weakness in limb and diaphragm muscles starting at 3 months.
  • MDR muscles displayed eccentric contraction-induced damage, fibrosis, and degenerative changes.

Conclusions:

  • The developed muscular dystrophy rat (MDR) model effectively recapitulates key features of human Duchenne muscular dystrophy.
  • This model demonstrates significant, progressive muscle functional deficits and pathology.
  • The MDR rat is a valuable preclinical tool for evaluating novel therapeutic strategies for DMD.